Landos Biopharma LABP Stock
Landos Biopharma Price Chart
Landos Biopharma LABP Financial and Trading Overview
| Landos Biopharma stock price | 21.54 USD |
| Previous Close | 3.91 USD |
| Open | 3.9 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 3200 |
| Day's Range | 3.8 - 4.02 USD |
| 52 Week Range | 2.11 - 13.7 USD |
| Volume | 10.69K USD |
| Avg. Volume | 20.09K USD |
| Market Cap | 11.84M USD |
| Beta (5Y Monthly) | -1.152694 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.5 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.5 USD |
LABP Valuation Measures
| Enterprise Value | -37819136 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0555556 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.25187248 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.181 |
Trading Information
Landos Biopharma Stock Price History
| Beta (5Y Monthly) | -1.152694 |
| 52-Week Change | -51.83% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.7 USD |
| 52 Week Low | 2.11 USD |
| 50-Day Moving Average | 3.07 USD |
| 200-Day Moving Average | 4.11 USD |
LABP Share Statistics
| Avg. Volume (3 month) | 20.09K USD |
| Avg. Daily Volume (10-Days) | 43.61K USD |
| Shares Outstanding | 3.12M |
| Float | 1.28M |
| Short Ratio | 0.35 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 8.08K |
| Short % of Float | 0.50% |
| Short % of Shares Outstanding | 0.26% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.43% |
| Return on Equity (ttm) | -55.79% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -32018750 USD |
| Net Income Avi to Common (ttm) | -30446000 USD |
| Diluted EPS (ttm) | -7.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 50.01M USD |
| Total Cash Per Share (mrq) | 16.04 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 12.304 |
| Book Value Per Share (mrq) | 15.087 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -37439000 USD |
| Levered Free Cash Flow (ttm) | -27698876 USD |
Profile of Landos Biopharma
| Country | United States |
| State | VA |
| City | Blacksburg |
| Address | 1800 Kraft Drive |
| ZIP | 24060 |
| Phone | 540 218 1767 |
| Website | https://landosbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Q&A For Landos Biopharma Stock
What is a current LABP stock price?
Landos Biopharma LABP stock price today per share is 21.54 USD.
How to purchase Landos Biopharma stock?
You can buy LABP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Landos Biopharma?
The stock symbol or ticker of Landos Biopharma is LABP.
Which industry does the Landos Biopharma company belong to?
The Landos Biopharma industry is Biotechnology.
How many shares does Landos Biopharma have in circulation?
The max supply of Landos Biopharma shares is 3.12M.
What is Landos Biopharma Price to Earnings Ratio (PE Ratio)?
Landos Biopharma PE Ratio is now.
What was Landos Biopharma earnings per share over the trailing 12 months (TTM)?
Landos Biopharma EPS is -3.5 USD over the trailing 12 months.
Which sector does the Landos Biopharma company belong to?
The Landos Biopharma sector is Healthcare.
Landos Biopharma LABP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}